Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (NASDAQ:GLUE), sold shares of common stock on May 27, 2026, following the exercise of stock options. The transactions were conducted under a Rule 10b5-1 trading plan adopted on February 19, 2026.
Ms. Champoux disposed of 2,175 shares at $20.0 per share, totaling $43,500. The sale immediately followed her acquisition of an equal number of shares through the exercise of stock options.
The acquisition involved 2,175 shares at an exercise price of $3.98 per share, amounting to $8,656. The option was part of a grant where 25% vested on May 28, 2025, with the rest vesting in 36 monthly installments, subject to her continued service.
Following these transactions, Ms. Champoux directly holds 62,371 shares of common stock and retains 35,649 stock options. GLUE shares have surged 378% over the past year but trade above Bond.az Fair Value, suggesting possible overvaluation. The company's market cap stands at $1.62 billion.
In other news, Monte Rosa reported Q4 2025 results and plans Phase 2 studies for NEK7, GSPT1, and VAV1. Jefferies and Guggenheim lowered price targets to $30 but maintained Buy ratings.
